ImmunoVaccine (IMV: CA) Forms Inaugural Scientific and Clinical Advisory Committee

ImmunoVaccine Inc. (IMV: CA) has formed an inaugural scientific and clinical advisory committee (SCAC) comprising academic and industry experts in disease areas in which ImmunoVaccine focuses: immuno-oncology and virology.

The Committee will provide counsel for the company’s research and development activities and access to cutting-edge ideas through collaborative data sharing and insight. Committee members will also help shape clinical programs based on real-world successes and unbiased perspectives that are founded in deep clinical research and field experience.

“We’re honored to have assembled a team of distinguished industry researchers, clinicians and collaborators to help guide strategy as we advance and expand our research and clinical programs,” said Frederic Ors, ImmunoVaccine’s Chief Executive Officer. “Each member brings an impressive pedigree and expertise that directly supports the disease indications we are targeting using our proprietary DepoVax platform. With backgrounds in virology, immunotherapy and infectious diseases, their collective experience will be invaluable as we work to bring much-needed therapies to the market for patients.”

The Scientific and Clinical Advisory Committee members include:

Barney Graham, PhD, MD

Senior Investigator, Viral Pathogenesis Laboratory, National Institute of Allergy

and Infectious Diseases Vaccine Research Center

National Institutes of Health

Scott Halperin, MD

Director

Canadian Centre for Vaccinology

Ramy Ibrahim, MD

Vice President, Clinical Development

Parker Institute for Cancer Immunotherapy

James Johnston, MB, BCh, FRCPC

Senior Scientist, Research Institute in Oncology and Hematology

Cancer Care Manitoba

Grant McFadden, PhD

Director, Biodesign Center for Immunotherapy, Vaccines and Virotherapy

Arizona State University

Michael Aaron Morse, MD

Professor of Medicine and Professor in the Department of Surgery

Duke University Medical Center

Brad Nelson, PhD

Director and Distinguished Scientist, Deeley Research Centre

BC Cancer Agency

Kunle Odunsi, PhD, MD, FRCOG, FACOG

Cancer Center Deputy Director; Chair of the Department of Gynecologic

Oncology; and Executive Director, Center for Immunotherapy

Roswell Park Cancer Institute

David Spaner, PhD, MD

Senior Scientist, Biological Sciences, Odette Cancer Research Program

Sunnybrook Research Institute

Pramod Srivastava, PhD, MD

Director, Center for Immunotherapy of Cancer and Infectious Diseases

Eversource Energy Chair in Experimental Oncology

Director of The Carole and Ray Neag Comprehensive Cancer Center

University of Connecticut School of Medicine

About ImmunoVaccine

ImmunoVaccine Inc. is a clinical-stage biopharmaceutical company dedicated to making immunotherapy more effective, more broadly applicable, and more widely available to people facing cancer and infectious diseases. ImmunoVaccine develops T cell activating cancer immunotherapies and infectious disease vaccines based on DepoVax, the Company’s patented platform that provides controlled and prolonged exposure of antigens and adjuvant to the immune system. ImmunoVaccine has advanced two T cell activation therapies for cancer through Phase 1 human clinical trials and is currently conducting a Phase 1b study with Incyte Corporation assessing lead cancer therapy, DPX-Survivac, as a combination therapy in ovarian cancer. The Company is also exploring additional applications of DepoVax, including DPX-RSV, an innovative vaccine candidate for respiratory syncytial virus (RSV), which has recently completed a Phase 1 clinical trial. ImmunoVaccine also has ongoing clinical projects to assess the potential of DepoVax to address malaria and the Zika virus. Connect at www.imvaccine.com.

In the interest of full disclosure, we call the reader’s attention to the fact that Equities.com, Inc. is compensated by the companies profiled in the Spotlight Companies section. The purpose of these profiles is to provide awareness of these companies to investors in the micro, small-cap and growth equity community and should not in any way be considered as a recommendation to buy, sell or hold these securities. Equities.com is not a registered broker dealer, investment advisor, financial analyst, investment banker or other investment professional. We are a publisher of original and third party news and information. All profiles are based on information that is available to the public. The information contained herein should not be considered to be complete and is not guaranteed by Equities.com to be free from misstatement or errors. The views expressed are our own and not intended to be the basis for any investment decision. Readers are reminded to do their own due diligence when researching any companies mentioned on this website. Always bear in mind that investing in early-stage companies is risky and you are encouraged to only invest an amount that you can afford to lose completely without any change in your lifestyle. Equities has been compensated with cash, common shares and/or warrants for market awareness services provided